5PSQ-048 Abstract withdrawn

<h3>Background and Importance</h3> Ustekinumab (anti-IL-12/23), golimumab (anti-TNF) and guselkumab (anti-IL-23) are specific immunosuppressants targeting molecules involved in inflammatory and immune response. <h3>Aim and Objectives</h3> To describe the prevalence of infection with real-life data in patients treated with ustekinumab, golimumab or guselkumab in their funded indications in the national health system. <h3>Material and Methods</h3> A retrospective observational study between December 2010 and August 2024 that included patients treated with ustekinumab, golimumab and guselkumab for at least 3 months, given the long half-life of these drugs (2–3 weeks). Demographic and clinical variables and the different infections recorded in primary and hospital care during the period of treatment were collected from the medical history. <h3>Results</h3> Forty-seven patients were included with ustekinumab (20/47), golimumab (17/47), guselkumab (10/47). The median age at baseline was 52.5 years (IQR 47–57), with 50% being female. In 23.4% of cases (11/47) the patient received concomitant systemic immunosuppressive therapy with leflunomide (5/11), methotrexate (4/11) and azathioprine (2/11) Median follow-up was 19.9 months (IQR 8.8–54.7) with a median persistence of 13.9 months (IQR 6.9–48.9). The reasons for discontinuation were: lack of response (24/26) or adverse events (2/26). Patients were vaccinated for SARS-Cov2 (30/45), influenza virus (29/45), diphtheria-tetanus (27/45), pneumococcus (27/45), hepatitis B virus (18/45), hepatitis A virus (10/45), varicella-zoster virus (3/45), <i>Haemophilus influenzae</i> (2/45). The median prevalence of infection per patient during treatment was 1 infection (IQR 0–2). We detected a total of 31 infections pertaining to 7 organs/systems, as detailed in the table. There were no serious infections, 4/31 were moderate and the rest (27/31) were mild. <h3>Conclusion and Relevance</h3> We found a low prevalence of infection in patients treated with ustekinumab, golimumab and guselkumab. Upper respiratory tract infections, followed by skin and soft-tissue infections and urinary tract infections, are the most frequent. In 90% of cases these infections were mild. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest